公开(公告)号：AU2006348662A1

公开(公告)日：2008-04-03

申请号：AU2006348662

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  PAN ZHENGYING ,  VERNER ERIK

IPC: A01N43/90 ,  A61K31/519 ,  A61K31/52 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：ES2590905T3

公开(公告)日：2016-11-24

申请号：ES13166272

申请日：2010-10-12

Applicant: PHARMACYCLICS INC

Inventor： CHEN WEI ,  LOURY DAVID J ,  MODY TARAK D ,  VERNER ERIK ,  SMYTH MARK STEPHEN ,  LUO WENCHEN

IPC: C07D487/04 ,  A61K31/519 ,  A61P19/02 ,  A61P19/10

Abstract: Un compuesto que tiene la estructura:**Fórmula** o una sal farmacéuticamente aceptable del mismo.

公开(公告)号：CY1112513T1

公开(公告)日：2015-12-09

申请号：CY121100100

申请日：2012-01-27

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

IPC: A01N43/90 ,  A61K31/519 ,  A61P35/00 ,  C07D487/04

Abstract: Αποκαλύπτονταιεδώενώσεις, οιοποίεςσχηματίζουνομοιοπολικούςδεσμούςμεκινάσεςτυροσίνηςτουΒruton (Βtk). ΕπίσηςπεριγράφονταιμηαναστρέψιμοιαναστολείςτηςΒtk. Αποκαλύπτονταιμέθοδοιγιατηνπαρασκευήτωνενώσεων. Επίσηςαποκαλύπτονταιφαρμακευτικέςσυνθέσειςπουπεριλαμβάνουντιςενώσεις. ΑποκαλύπτονταιμέθοδοιχρήσηςτωναναστολέωντηςΒtk μόνωνή σεσυνδυασμόμεάλλουςθεραπευτικούςπαράγοντεςγιατηνθεραπευτικήαγωγήαυτοάνοσωνασθενειώνή καταστάσεων, ετεροάνοσωνασθενειώνή καταστάσεων, καρκίνου, συμπεριλαμβανομένουλεμφώματοςκαιφλεγμονωδώνασθενειώνή καταστάσεων.

公开(公告)号：SG10201503235VA

公开(公告)日：2015-06-29

申请号：SG10201503235V

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：EA020001B1

公开(公告)日：2014-07-30

申请号：EA201000599

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

IPC: C07D487/04 ,  A61K31/519 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08

Abstract: Визобретенииприведеноописаниесоединений, образующихковалентныесвязис тирозинкиназойБрутона (Btk), инеобратимыхингибиторов Btk. Описаныспособыполучениятакихсоединений, атакжефармацевтическиекомпозиции, содержащиетакиесоединения. Крометого, приведеноописаниеспособовпримененияингибиторов Btk отдельноилив комбинациис другимитерапевтическимиагентамидлялеченияаутоиммунныхзаболеванийилисостояний, гетероиммунныхзаболеванийилисостояний, рака, включаялимфому, ивоспалительныхзаболеванийилисостояний.

公开(公告)号：EA017865B1

公开(公告)日：2013-03-29

申请号：EA200901313

申请日：2008-03-27

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  BUGGY JOSEPH J ,  LOURY DAVID ,  CHEN WEI

IPC: A61K31/52 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  C07D253/06 ,  C07D473/34 ,  C07D487/04

Abstract: Впатентеописанынеобратимыеингибиторыкиназ, способысинтезатакихнеобратимыхингибиторови способыприменениятакихнеобратимыхингибиторовдлялеченияболезней. Описанытакжеметодыанализаи системыдляопределениясоответствующегонеобратимогоингибиторабелка, включаякиназу.

公开(公告)号：ZA201007561B

公开(公告)日：2012-09-26

申请号：ZA201007561

申请日：2010-10-22

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  PAN ZHENGYING ,  VERNER ERIK

IPC: A61K20060101 ,  A01N20060101 ,  A61P20060101

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：SI2201840T1

公开(公告)日：2012-06-29

申请号：SI200631249

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

IPC: A61K31/00 ,  A01N43/00 ,  A61P35/00 ,  C07D487/00

公开(公告)号：SG166093A1

公开(公告)日：2010-11-29

申请号：SG2010066017

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (no suitable figure)

公开(公告)号：MX2009003122A

公开(公告)日：2009-08-07

申请号：MX2009003122

申请日：2006-12-28

Applicant: PHARMACYCLICS INC

Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

IPC: A61K31/519 ,  A01N43/90

Abstract: En la presente invención de describen compuestos que forman enlaces covalentes con tirosina cinasa de Bruton (Btk); también se describen inhibidores irreversibles de Btk; se describen métodos para la preparación de los compuestos; también de escriben composiciones farmacéuticas que incluyen los compuestos; se describen métodos de uso de los inhibidores de Brk, solos o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, y enfermedades o condiciones inflamatorias.